Free Trial

Ikena Oncology Q3 2023 Earnings Report

Ikena Oncology logo
$1.66 -0.03 (-1.78%)
As of 04:00 PM Eastern

Ikena Oncology EPS Results

Actual EPS
-$0.40
Consensus EPS
-$0.44
Beat/Miss
Beat by +$0.04
One Year Ago EPS
N/A

Ikena Oncology Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Ikena Oncology Announcement Details

Quarter
Q3 2023
Time
N/A

Conference Call Resources

Ikena Oncology Earnings Headlines

William Blair Reaffirms Their Buy Rating on Ikena Oncology (IKNA)
Buy this Stock before Trump Takes Office!
We're issuing an urgent "buy alert" on a little-known "AI company" set to SOAR under this new administration. And it's not just because it hit a critical "buy now" price.
Ikena Oncology, Inmagene Biopharmaceuticals to Merge
See More Ikena Oncology Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Ikena Oncology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Ikena Oncology and other key companies, straight to your email.

About Ikena Oncology

Ikena Oncology (NASDAQ:IKNA) operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States. Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway. The company also develops IK-595, a molecular glue designed to trap MEK and RAF in an inactive complex. Ikena Oncology, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

View Ikena Oncology Profile

More Earnings Resources from MarketBeat